India-based Ranbaxy will market Zonisamide capsules
for the treatment of epilepsy in the U.S. through a partnership with Invagen
Pharmaceuticals, the company announced. Zonisamide, indicated as adjunctive
therapy in the treatment of partial seizures in adults with epilepsy, is the
generic equivalent of Eisai Pharmaceutical's Zonegran.
The agreement with Invagen provides for products to be developed and submitted to the FDA for approval. Ranbaxy will commercialize the product.
"The addition of Zonisamide
to our product mix through an alliance
with Invagen reinforces our strategy to use inorganic means to grow our product
pipeline, as well. Such partnerships with companies like Invagen, who have capabilities
and competencies to develop bioequivalent generic products for the marketplace,
are naturally beneficial to both organizations, while having a positive economic
impact on the U.S. healthcare system," said Atul Malhotra, president of